HopeMed's Breakthrough in Endometriosis Treatment: A Promising Step Forward

Hope Medicine Inc. has announced promising results from a Phase 2 study of HMI-115, a novel treatment for endometriosis-related pain. The study demonstrated significant pain reduction and safety, with no significant hormone disruption, aiding women with endometriosis in managing their symptoms effectively.

Hope Medicine Inc., known as HopeMed, is making strides in the treatment of endometriosis with its innovative drug, HMI-115. An interim analysis of a Phase 2 global study revealed that the monoclonal antibody significantly reduces pain associated with the condition, without altering sex-steroid hormones.

The trial, involving 142 women from the US, Poland, and China, showed a remarkable 42% reduction in dysmenorrhea pain scores and a 50% decrease in non-menstrual pelvic pain. The drug was well-tolerated, with no serious side effects reported, and it maintains normal menstrual cycles by preserving natural hormonal balance.

Experts are optimistic about HMI-115's potential. Dr. Hugh Taylor emphasized its promise in fulfilling an unmet medical need, while Dr. Jeffrey Jensen noted its non-contraceptive benefits. Hope Medicine plans to expedite Phase 3 trials, aiming to provide this pioneering treatment to women worldwide.

(With inputs from agencies.)